

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

NINTEDANIB ESILATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the nintedanib esilate powder for inhalation (the “**Product**”) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is the first inhalation formulation approved for clinical use in China for the treatment of pulmonary fibrosis. Nintedanib esilate is a multi-target tyrosine kinase inhibitor indicated for slowing the progression of idiopathic pulmonary fibrosis (IPF). Currently, the marketed dosage form is an oral soft capsule. Compared with oral formulation, the Product offers the advantages of significantly increasing local pulmonary exposure, notably improving lung function, lowering systemic exposure, and significantly reducing gastrointestinal adverse effects. Preclinical studies indicated that the Product achieved comparable therapeutic effects at 1/200 of the oral dose and exhibited a favorable safety profile and effectiveness.

The indication for this clinical trial approval is idiopathic pulmonary fibrosis. In addition, the Product also has potential for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive pulmonary fibrosis (PPF). The Product represents a key achievement of the Group’s inhalation technology platform, and its clinical trial approval lays a solid foundation for the development of subsequent inhalation formulations within the Group’s pipeline.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 2 January 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong, as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.